Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lavinia Drambarean

Physician Assistant Hattiesburg, MS Physician Assistant

NPI 1871849372 CMS profile 11159912

3 Thompson Park, Hattiesburg, MS 39401

Open in the dashboard

General payments

$381,569

1,555 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lavinia Drambarean of Hattiesburg, MS is reported in the CMS Open Payments database as having received $381,569 across 1,555 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180,189 427
2024 General $129,066 416
2023 General $52,652 309
2022 General $17,203 234
2021 General $2,459 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lavinia Drambarean
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lavinia Drambarean were reported at $180,189. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lavinia Drambarean Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,459 $132 $37–$438 $132
2022 $17,203 $155 $48–$522 $149
2023 $52,652 $167 $52–$557 $160
2024 $129,066 $178 $55–$600 $164
2025 $180,189 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $141,133 182 payments
  2. Lilly USA, LLC $55,129 125 payments
  3. AbbVie, Inc. $52,726 319 payments
  4. E.R. Squibb & Sons, L.L.C. $38,358 138 payments
  5. Regeneron Healthcare Solutions, Inc. $28,176 125 payments
  6. Incyte Corporation $24,752 96 payments
  7. Genzyme Corporation $23,551 75 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $4,605 64 payments
  9. Eli Lilly and Company $3,695 3 payments
  10. LEO Pharma Inc. $2,051 41 payments
  11. Other $7,393 387 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $241,418 185 payments
  2. Travel and Lodging $89,260 151 payments
  3. Food and Beverage $26,871 1,183 payments
  4. Consulting Fee $23,395 23 payments
  5. Education $625 13 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $141,077 172 payments
  2. TALTZ $40,492 94 payments
  3. SOTYKTU $33,935 125 payments
  4. OPZELURA $24,662 95 payments
  5. RINVOQ $24,495 109 payments
  6. DUPIXENT Immunology $23,883 87 payments
  7. DUPIXENT Inflammation And Immunology $16,350 86 payments
  8. SKYRIZI $13,788 125 payments
  9. EBGLYSS $13,350 28 payments
  10. DUPIXENT Immunology And Inflammation $11,813 38 payments
  11. Other $28,465 698 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,131

Median for Physician Assistant: 241

Drug cost

$855,516

Median for Physician Assistant: $4,110

Branded share of claims

12.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 15 $324,990
Rinvoq Upadacitinib Brand 35 $220,173
Dupixent Pen Dupilumab Brand 49 $193,467
Taltz Autoinjector Ixekizumab Brand 13 $89,353
Ketoconazole Generic 213 $5,035
Betamethasone Valerate Generic 154 $4,634
Metronidazole Generic 25 $1,930
Tacrolimus Generic 25 $1,919
Dutasteride Generic 54 $1,630
Betamethasone Dipropionate Generic 26 $1,480

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$59,594

Of which drugs: $3,611

Medicare patients

322

Average age 73

Services billed

2,445

185 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 41%
Diabetes 31%
Depression 24%
Chronic kidney disease 22%
Atrial fibrillation 17%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 29 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$53,953 — —
DUPIXENT
$23,055 49 —
SOTYKTU
$15,372 — —
RINVOQ
$13,554 35 —
SKYRIZI
$12,237 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,555 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record